In July 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) issued strengthened safety advice concerning botulinum toxin type A products following rare reports of iatrogenic botulism.
For aesthetic practitioners, the update is an important reminder that botulinum toxin is a prescription-only medicine and that safe treatment depends on appropriate prescribing, authorised supply, correct administration, patient selection and clear post-treatment safety-netting.
What has the MHRA said?
The MHRA advised healthcare professionals to remain alert to the rare risk of iatrogenic botulism following treatment with botulinum toxin. Symptoms typically occur within 4–8 days after treatment, although onset can be delayed for up to four weeks.
The regulator is strengthening product information across UK-authorised botulinum toxin type A products to make this risk clearer.
What is iatrogenic botulism?
Iatrogenic botulism is a rare but potentially serious complication caused by the systemic effects of botulinum neurotoxin following medical or aesthetic administration.
Symptoms can include generalised muscle weakness, difficulty swallowing, difficulty speaking, drooping eyelids, double or blurred vision and breathing difficulties. These symptoms require urgent medical assessment.
Which factors may increase the risk?
The MHRA highlights several circumstances that may increase risk, including underlying disorders that predispose a patient to neuromuscular weakness, higher doses, off-label use or administration at unapproved sites, and the use of counterfeit or unauthorised products.
Practitioners should therefore consider both the patient and the product. A technically competent injection does not compensate for inadequate medical assessment or an unreliable supply chain.
Why authorised sourcing matters
Botulinum toxin products used in UK clinical practice should come through legitimate, traceable supply routes. Counterfeit or unauthorised medicines can create risks around identity, potency, storage, handling and traceability.
Longeva Pharma supplies prescription-only medicines only against a valid prescription and through regulated pharmacy processes. Practitioners should maintain clear records of the product used, batch details and treatment documentation so that adverse events can be investigated appropriately.
What should practitioners do before treatment?
Before administering botulinum toxin, practitioners should ensure that the patient has been appropriately assessed and that relevant medical history, contraindications and concurrent medicines have been considered. Treatment should be clinically justified and consistent with the prescription and the practitioner's competence.
Practitioners should also confirm the provenance of the medicine, check packaging and batch information, follow the authorised product information, and ensure appropriate storage and handling requirements have been maintained.
What should patients be told?
Patients should receive clear safety-netting information. They should understand that symptoms associated with systemic toxin effects can develop after they have left the clinic and may not occur immediately.
Patients should be advised to seek urgent medical attention if they develop difficulty breathing or swallowing, marked or progressive weakness, speech problems, significant visual disturbance or other concerning neurological symptoms after treatment.
What if iatrogenic botulism is suspected?
Suspected botulism should not be managed as a routine aesthetic complication. The patient requires urgent medical assessment and escalation according to the severity of their symptoms.
Practitioners should provide relevant treatment information to the assessing medical team, including the product, dose, treatment date, injection sites and batch details where available.
Reporting suspected adverse reactions
Suspected adverse drug reactions should be reported through the MHRA Yellow Card scheme. Reporting contributes to medicines-safety surveillance and helps regulators identify emerging patterns.
What this means for aesthetic practice
The MHRA update does not suggest that appropriately used, authorised botulinum toxin products are broadly unsafe. It reinforces the responsibilities that already sit around prescription medicines: appropriate assessment, lawful prescribing, legitimate sourcing, correct administration, documentation, patient information and prompt escalation when red-flag symptoms occur.
For practitioners, the practical message is straightforward: know the medicine, know the patient, know the supply chain and make sure the patient knows when to seek help.
Further information
Practitioners should review the current MHRA Drug Safety Update and the Summary of Product Characteristics and Patient Information Leaflet for the specific botulinum toxin product they use. Suspected adverse reactions can be reported through the MHRA Yellow Card scheme.
This article is intended for healthcare and aesthetic professionals and is for general educational purposes. It does not replace the authorised product information, professional clinical judgement, local protocols or individual patient assessment.